Eli Lilly and (LLY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Eli Lilly and

NYSE•Healthcare•Drug Manufacturers - General

$1,409.38-1.61(<0.01%)After hours

Market Cap

$1.26T

P/E

45.6x

P/S

14.6x

P/B

31.2x

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

How this company scores

GoodMetricSide Score: 79/100

Strongest: Growth (25/25); weakest: Balance Sheet & Red Flags (14/25).

Profitability22/25

Growth25/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality18/25

Strengths

Growing revenueRising free cash flowStrong marginsHigh ROE

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 45.6x5y range 31.4x – 145.4x

Currently below its 20-quarter median.

P/S · 14.6x5y range 11.0x – 26.2x

Currently below its 20-quarter median.

P/B · 31.2x5y range 25.4x – 83.8x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.3x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.26T

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $86.46B
Q. Revenue: $24.40B
TTM EBITDA: $37.05B
TTM Op. Income: $34.88B
Q. Op. Income: $8.61B
TTM Net Income: $27.58B
Q. Net Income: $6.45B
EPS: N/A
Shares Out.: $891.90M

$86.46B in TTM revenue grew 45.5% YoY, reaching $24.40B last quarter. TTM EBITDA of $37.05B and TTM operating income of $34.88B show growth is flowing through to the bottom line. TTM net income of $27.58B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 37.5%
Op. Margin: 35.3%
Net Margin: 26.4%

Op. margin of 35.3% is down 6.6% YoY — costs are rising relative to revenue. Net margin at 26.4% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 45.6x
P/S Ratio: 14.6x
P/B Ratio: 31.2x

At 45.6x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 14.6x and P/B of 31.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 8 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $148.07B
Cash: $4.88B
Long-Term Debt: $46.99B
Book Value: $40.27B
D/E Ratio: 1.2
Debt/EBITDA: 5.1

With $148.07B in assets and $46.99B in long-term debt, D/E is 1.2and book value is $40.27B — moderate leverage. Over the past year, debt/equity is down 32% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $11.40B
TTM Free Cash Flow: $11.69B
FCF Margin: 13.5%
FCF / Net Income: 0.4

TTM FCF of $11.69B on $11.40B in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 82% — a weakening trend.